PALO ALTO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that it will report its third quarter 2009 financial results on Thursday, November 5, 2009. Jazz Pharmaceuticals will host an investor conference call and live webcast to give a company update, as well as to discuss financial results and guidance, on November 5, 2009, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
The live webcast and press release may be accessed from the Investors section of the Jazz Pharmaceuticals' website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archived version of the webcast will be available through November 19, 2009.
Investors may participate in the conference call by dialing 1-866-825-1692 in the U.S., or 1-617-213-8059 outside the U.S., and entering passcode 25459996.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information please see www.jazzpharmaceuticals.com.
SOURCE Jazz Pharmaceuticals, Inc.
Advertisement
The live webcast and press release may be accessed from the Investors section of the Jazz Pharmaceuticals' website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archived version of the webcast will be available through November 19, 2009.
Advertisement
Investors may participate in the conference call by dialing 1-866-825-1692 in the U.S., or 1-617-213-8059 outside the U.S., and entering passcode 25459996.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information please see www.jazzpharmaceuticals.com.
SOURCE Jazz Pharmaceuticals, Inc.
